Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HMPL-689 in Relapsed/Refractory Lymphoma
NCT03786926Phase 1Terminated
- Sponsor
- HUTCHMED
- Start
- Aug 2019
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of amdizatinib in non-Hodgkin lymphoma (NHL), sponsored by HUTCHMED. Primary endpoints: Number of Patients With Dose-Limiting Toxicities and Number of Patients With Treatment-Emergent Adverse Events. Started Aug 2019; status: terminated.
02
Drugs
amdizatinib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03786926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03786926.